CoronaryAtlas logo
CoronaryAtlas
B-type natriuretic peptide
Pathway / Off-pathway / systemic markers

B-type natriuretic peptide

NPPBprotein

BNP reflects post-infarction cardiac insufficiency and hemodynamic strain, operating off the atherothrombotic axis.

Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencehigh
RationaleAnchor molecule s0; cardiac remodeling and hemodynamic stress marker, not atherothrombotic cascade.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000120937

Type I vs non-Type I discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — non-Type-I
53
A — assay feasibility
96
E — evidence strength
67
T1DI (composite)
33
Specificity differential (R−C)+1.4
Direct evidence: higher in non-Type I (D=-1)
NT-proBNP: 10,327 +/- 12,923 ng/L in T2-MI vs 4675 +/- 11,740 ng/L in T1-MI (P=0.006); a second cohort found no T1/T2 discrimination
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
2hypovolemia / dehydrationmag 2
2tachyarrhythmiamag 1
2hypoxemia / respiratory failuremag 1
2hypertensive emergencymag 2
2high-demand / peri-operative stressmag 1
3sudden cardiac deathmag 1
4aPCI-related periproceduralmag 2
4bstent thrombosisn/a
4cin-stent restenosismag 2
5CABG-relatedmag 2
Coverage: 10/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 18 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Plasma (BNP: EDTA required); serum/plasma (NT-proBNP)
Collection tube
K2-EDTA, chilled plastic (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
Chemiluminescent sandwich immunoassay
Reagent / substrate
Anti-BNP or anti-NT-proBNP antibody pair
Platform
Automated analyzer; POC (Alere Triage)
Turnaround · availability
STAT (~15–30 min) · FDA-cleared

Human genetic evidence

0.026
Open Targets association (STEMI)

Literature evidence(60)

Showing 40 of 60 linked references.

Clinical trials(1)